Abstract: A cooling member located in an upper part of a battery cell stack in which a plurality of battery cells are stacked includes an upper plate, a lower plate, and a coolant incorporated in an inner space between the upper plate and the lower plate. The lower plate includes a first part in which a fragile part is formed, and a second part in which the fragile part is not formed. A thickness value of the first part is smaller than a thickness value of the second part.

Abstract: The present disclosure relates to a method for preparing a non-woven fabric which improves impregnation and release properties of a fabric softener in the non-woven fabric in order to apply the non-woven fabric to a dryer sheet (sheet-type fabric softener). When increasing porosity and specific surface area in a non-woven fabric made of two-component blended polyester long fibers, impregnation and release rate of a fabric softener are improved even when the non-woven fabric is lightened, making it possible to apply the non-woven fabric to a dryer sheet.

Abstract: A battery control method includes detecting charge state information including a charge current, a discharge current, and an SOC of the battery, detecting whether the SOC of the battery reaches a predetermined reference SOC using the charge state information, and determining when the SOC of the battery reaches the reference SOC as a first reference time point and when the SOC of the battery reaches the reference SOC after the first reference time point as a second reference time point, calculating a charge capacity of the battery using a charge current from the first time point to the second time point and a discharge capacity of the battery using the discharge current, comparing a difference between the charge capacity and the discharge capacity, and determining that an internal short circuit of the battery occurs when the difference between the charge capacity and the discharge capacity exceeds a threshold value.

Abstract: In a method of controlling a battery system having a battery module comprising a plurality of battery sub modules connected in parallel between system terminals, the method includes: measuring voltage values of the plurality of battery sub modules and/or cells in the plurality of battery sub modules and current values that flow on the battery module; detecting an occurrence of an internal short in the battery module by monitoring the voltage values or the current values; and electrically separating at least one battery sub module in which the internal short occurs from among the plurality of battery sub modules from the system terminals in response to the internal short occurring in the battery module.

Abstract: In a method for detecting an internal short of a battery, the method includes: acquiring first charge state information related to a charge state of the battery; detecting a first reference time point when the first charge state information satisfies a reference condition; acquiring second charge state information related to the charge state of the battery; detecting a second reference time point when the second charge state information satisfies a reference condition; and detecting an internal short of the battery based on a difference between a charge amount from the first reference time point to the second reference time point and a discharge amount from the first reference time point to the second reference time point.

Abstract: In a method for detecting an internal short of a battery, the method includes: measuring a voltage of a battery a plurality of times; and determining whether or not the internal short of the battery occurs based on a difference between a first voltage value of the battery during a first time period and a second voltage value of the battery during a second time period when the battery is in constant current charging, wherein the second time period is a time period after the first time period.

Abstract: In a method of controlling a battery system having a battery module comprising a plurality of battery sub modules connected in parallel between system terminals, the method includes: measuring voltage values of the plurality of battery sub modules and/or cells in the plurality of battery sub modules and current values that flow on the battery module; detecting an occurrence of an internal short in the battery module by monitoring the voltage values or the current values; and electrically separating at least one battery sub module in which the internal short occurs from among the plurality of battery sub modules from the system terminals in response to the internal short occurring in the battery module.

Abstract: A battery control method includes detecting charge state information including a charge current, a discharge current, and an SOC of the battery, detecting whether the SOC of the battery reaches a predetermined reference SOC using the charge state information, and determining when the SOC of the battery reaches the reference SOC as a first reference time point and when the SOC of the battery reaches the reference SOC after the first reference time point as a second reference time point, calculating a charge capacity of the battery using a charge current from the first time point to the second time point and a discharge capacity of the battery using the discharge current, comparing a difference between the charge capacity and the discharge capacity, and determining that an internal short circuit of the battery occurs when the difference between the charge capacity and the discharge capacity exceeds a threshold value.

Abstract: In a method for detecting an internal short of a battery, the method includes: acquiring first charge state information related to a charge state of the battery; detecting a first reference time point when the first charge state information satisfies a reference condition; acquiring second charge state information related to the charge state of the battery; detecting a second reference time point when the second charge state information satisfies a reference condition; and detecting an internal short of the battery based on a difference between a charge amount from the first reference time point to the second reference time point and a discharge amount from the first reference time point to the second reference time point.

Abstract: In a method for detecting an internal short of a battery, the method includes: measuring a voltage of a battery a plurality of times; and determining whether or not the internal short of the battery occurs based on a difference between a first voltage value of the battery during a first time period and a second voltage value of the battery during a second time period when the battery is in constant current charging, wherein the second time period is a time period after the first time period.

Abstract: The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

Abstract: The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

Abstract: The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

Abstract: The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

Abstract: The invention provides methods of detecting cancer and detecting activity of IDH inhibitors, and methods of screening for IDH inhibitors by detecting levels of H3K9me2.

Abstract: The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

Abstract: The invention is directed to novel pyrrolopyrimidine compounds of formula (1) wherein R1, R2y, R4, R8-R11, A and L are defined herein and to salts, including pharmaceutically acceptable salts thereof. The compounds of the present invention are CDK4/6 inhibitors and could be useful in the treatment of diseases and disorders mediated by CDK4/6, such as cancer, including mantle cell lymphoma, liposarcoma, non small cell lung cancer, melanoma, squamous cell esophageal cancer and breast cancer. The invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CDK4/6 activity and to the treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Abstract: The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are described herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant I DH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

Abstract: A battery pack and a power generation circuit in the battery pack are disclosed. The battery pack includes a battery cell unit including battery cells connected in series, a charge/discharge switch connected between the battery cell unit and charge/discharge terminals, a charge/discharge controller controlling the charge/discharge switch to charge or discharge the battery cell unit, and a voltage converter electrically connected in parallel to the charge/discharge switch and dropping a voltage of the battery cell unit, and outputting the dropped voltage as power of the charge/discharge controller.

Abstract: The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.